--- title: "Anbio Biotechnology (NNNN) stock: news and investor profile" url: "https://aibio.space/companies/anbio-biotechnology/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "Anbio Biotechnology (NASDAQ: NNNN), United States. Listing facts, related biotech companies and news on aibio.space." --- NNNN Anbio Biotechnology NASDAQ · United States # Anbio Biotechnology (NNNN) news Anbio Biotechnology is a public biotech or pharmaceutical company listed on NASDAQ under the ticker NNNN, recorded under United States. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. ## Latest Anbio Biotechnology news We have not published a story on Anbio Biotechnology yet. When there is news, it will appear here. ## Anbio Biotechnology at a glance - **Ticker**: NNNN - **Listing**: NASDAQ - **Country**: United States - **Cash, Dec 31, 2025**: $11.9 million ### Related companies - [Black Hawk Acquisition](https://aibio.space/companies/black-hawk-acquisition/) NASDAQ: BKHA - [Bionano Genomics](https://aibio.space/companies/bionano-genomics/) NASDAQ: BNGO - [Picard Medical](https://aibio.space/companies/picard-medical/) NYSE: PMI - [Cannabis Bioscience International Holdings](https://aibio.space/companies/cannabis-bioscience-international/) OTC: CBIH - [CollPlant Biotechnologies](https://aibio.space/companies/collplant-biotechnologies/) NASDAQ: CLGN - [Electromedical Technologies](https://aibio.space/companies/electromedical-technologies/) OTC: EMED - [METTLER TOLEDO INTERNATIONAL INC/](https://aibio.space/companies/mettler-toledo-international/) NYSE: MTD - [Medline](https://aibio.space/companies/medline/) NASDAQ: MDLN ### Also on NASDAQ - [CervoMed](https://aibio.space/companies/cervomed/) CRVO - [Oncolytics Biotech](https://aibio.space/companies/oncolytics-biotech/) ONCY - [BeyondSpring](https://aibio.space/companies/beyondspring/) BYSI - [Eton Pharmaceuticals](https://aibio.space/companies/eton-pharmaceuticals/) ETON - [enGene Therapeutics](https://aibio.space/companies/engene-therapeutics/) ENGN - [Celldex Therapeutics](https://aibio.space/companies/celldex-therapeutics/) CLDX ## Anbio Biotechnology annual financials | Line | FY2025 | FY2024 | |---|---|---| | Revenue | [$8.6 million](https://www.sec.gov/Archives/edgar/data/1982708/000118518526001294/) | [$8.2 million](https://www.sec.gov/Archives/edgar/data/1982708/000118518526001294/) | | Research and development | [$201,305](https://www.sec.gov/Archives/edgar/data/1982708/000118518526001294/) | [$454,227](https://www.sec.gov/Archives/edgar/data/1982708/000118518526001294/) | | Net income (loss) | [$6.4 million](https://www.sec.gov/Archives/edgar/data/1982708/000118518526001294/) | [$2.4 million](https://www.sec.gov/Archives/edgar/data/1982708/000118518526001294/) | | Cash from operations | [-$6.7 million](https://www.sec.gov/Archives/edgar/data/1982708/000118518526001294/) | [$2.1 million](https://www.sec.gov/Archives/edgar/data/1982708/000118518526001294/) | | Cash and equivalents | [$7.8 million](https://www.sec.gov/Archives/edgar/data/1982708/000118518526001294/) | [$11.8 million](https://www.sec.gov/Archives/edgar/data/1982708/000118518526001294/) | | Short-term investments | [$4.1 million](https://www.sec.gov/Archives/edgar/data/1982708/000118518526001294/) | [$0](https://www.sec.gov/Archives/edgar/data/1982708/000118518526001294/) | Latest balance sheet, Dec 31, 2025 (20-F): cash and equivalents $7.8 million, plus short-term investments of $4.1 million, $11.9 million in all. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Anbio Biotechnology What is the ticker symbol of Anbio Biotechnology? Anbio Biotechnology trades under the ticker NNNN on NASDAQ. Where is Anbio Biotechnology listed? Anbio Biotechnology is listed on NASDAQ. Which country or territory is Anbio Biotechnology listed under? Our directory records Anbio Biotechnology under United States. Does aibio.space cover Anbio Biotechnology? aibio.space lists Anbio Biotechnology among 2,820 public biotech companies and publishes its news here as stories appear. What was Anbio Biotechnology's revenue last year? $8.6 million for the fiscal year ended Dec 31, 2025, as reported to the SEC. Is Anbio Biotechnology profitable? Anbio Biotechnology reported net income of $6.4 million for the fiscal year ended Dec 31, 2025, and used $6.7 million of cash in operations, per its annual report to the SEC. How much does Anbio Biotechnology spend on research and development? $201,305 in the fiscal year ended Dec 31, 2025, per its annual report. How much cash does Anbio Biotechnology have? $11.9 million in cash and short-term investments at Dec 31, 2025, per its 20-F. ## Investor discussion: Anbio Biotechnology Members talk about Anbio Biotechnology (NNNN). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Anbio Biotechnology, newest first. Each line links the filing it comes from. 1. 2026-05-19 Listings Reported a reverse stock split. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1982708/000118518526001897/anbio6k051826.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:NNNN on TradingView](https://www.tradingview.com/symbols/NASDAQ-NNNN/). ## Listing details Anbio Biotechnology is a public biotech or pharmaceutical company listed on NASDAQ under the ticker NNNN, recorded under United States. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Anbio Biotechnology - **Ticker**: NNNN - **Listing**: NASDAQ - **Country or territory**: United States Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/anbio-biotechnology/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Anbio Biotechnology (NNNN) stock: news and investor profile", 2026-10-31, https://aibio.space/companies/anbio-biotechnology/